| Description |
TC11 is a MCL1 degradator and Caspase-9 and CDK1 activator. TC11 structurally relates to immunomodulatory drugs as phenylphthalimide derivative. TC11 induces apoptotic death caused by degradation of MCL1 during prolonged mitotic arrest[1][2].
|
| Related Catalog |
|
| Target |
CDK1
Caspase-9
MCL1
|
| In Vitro |
Cell Viability Assay[1] Cell Line: KMS34 cells Concentration: 0~30 μM Incubation Time: 24 hours Result: Induced cell death. Western Blot Analysis[1] Cell Line: KMS34 cells Concentration: 5 μM Incubation Time: 0~48 hours Result: Induced cell death occurs through an apoptotic pathway and downregulated MCL1 expression. Cell Cycle Analysis[1] Cell Line: KMS34 cells Concentration: 5 μM Incubation Time: 24 hours Result: Induced M arrest.
|
| In Vivo |
TC11 (0~30 μM; 24 hours; KMS34 cells) induces cell death in KMS34[1]. TC11 (5 μM; 0~48 hours; KMS34 cells) induces cell death occurs through an apoptotic pathway and downregulates MCL1 expression[1]. TC11 (5 μM; 24 hours; KMS34 cells) induces M arrest[1].
|
| References |
[1]. Ichikawa D, et al. A phenylphthalimide derivative, TC11, induces apoptosis by degrading MCL1 in multiple myeloma cells. Biochem Biophys Res Commun. 2020;521(1):252-258. [2]. Shiheido H, et al. A phthalimide derivative that inhibits centrosomal clustering is effective on multiple myeloma. PLoS One. 2012;7(6):e38878.
|
